Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma.

被引：0
|
作者：
Yang, JIwon
Choi, Won-Mook
Kim, Hyung-Don
Choi, Jonggi
Yoo, Changhoon
Lee, Danbi
Shim, Ju Hyun
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
机构：
[1] Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Univ Ulsan, Liver Ctr, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.558
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：558 / 558
页数：1
相关论文
共 50 条
  • [41] ATEZOLIZUMAB plus BEVACIZUMAB VERSUS OTHER SYSTEMIC THERAPIES FOR THE FIRST LINE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA: A SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON
    Amorim, M.
    Pereira, A.
    Rabiais, S.
    Vandewalle, B.
    Alarcao, J.
    VALUE IN HEALTH, 2022, 25 (01) : S186 - S186
  • [42] Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Lu, Jinpeng
    Lin, Xinyi
    Teng, Haiwen
    Zheng, Yansong
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (06): : 643 - 651
  • [43] SIMILAR EFFICACY AND SAFETY BETWEEN LENVATINIB VERSUS ATEZOLIZUMAB PLUS BEVACIZUMAB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Su, Chung-Wei
    Teng, Wei
    Lin, Po-Ting
    Jeng, Wen-Juei
    Chen, Kuei-An
    Hsieh, Yi-Chung
    Chen, Wei-Ting
    Hou, Ming-Mo
    Hsieh, Chia-Hsun
    Lin, Chen-Chun
    Lin, Chun-Yen
    Lin, Hsi-Ming
    HEPATOLOGY, 2022, 76 : S1415 - S1415
  • [44] Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma
    Zhou, Ting
    Cao, Yingdan
    Wang, Xintian
    Yang, Lan
    Wang, Zijing
    Ma, Aixia
    Li, Hongchao
    ADVANCES IN THERAPY, 2022, 39 (05) : 2165 - 2177
  • [45] Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma
    Ting Zhou
    Yingdan Cao
    Xintian Wang
    Lan Yang
    Zijing Wang
    Aixia Ma
    Hongchao Li
    Advances in Therapy, 2022, 39 : 2165 - 2177
  • [46] Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
    Chen, Ching-Tso
    Feng, Yin-Hsun
    Yen, Chia-Jui
    Chen, San-Chi
    Lin, Yun-Tzu
    Lu, Li-Chun
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    Shao, Yu-Yun
    HEPATOLOGY INTERNATIONAL, 2022, 16 (05) : 1199 - 1207
  • [47] Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
    Ching-Tso Chen
    Yin-Hsun Feng
    Chia-Jui Yen
    San-Chi Chen
    Yun-Tzu Lin
    Li-Chun Lu
    Chih-Hung Hsu
    Ann-Lii Cheng
    Yu-Yun Shao
    Hepatology International, 2022, 16 : 1199 - 1207
  • [48] Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
    Maesaka, Kazuki
    Sakamori, Ryotaro
    Yamada, Ryoko
    Doi, Akira
    Tahata, Yuki
    Miyazaki, Masanori
    Ohkawa, Kazuyoshi
    Mita, Eiji
    Iio, Sadaharu
    Nozaki, Yasutoshi
    Yakushijin, Takayuki
    Imai, Yasuharu
    Kodama, Takahiro
    Hikita, Hayato
    Tatsumi, Tomohide
    Takehara, Tetsuo
    HEPATOLOGY RESEARCH, 2022, 52 (07) : 630 - 640
  • [49] COMPARISON OF ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB IN TERMS OF EFFICACY AND SAFETY AS PRIMARY SYSTEMIC CHEMOTHERAPY FOR HEPATOCELLULAR CARCINOMA
    Maesaka, Kazuki
    Sakamori, Ryotaro
    Tahata, Yuki
    Doi, Akira
    Miyazaki, Masanori
    Ohkawa, Kazuyoshi
    Mita, Eiji
    Iio, Sadaharu
    Nozaki, Yasutoshi
    Yakushijin, Takayuki
    Oshita, Masahide
    Kodama, Takahiro
    Hikita, Hayato
    Tatsumi, Tomohide
    Takehara, Tetsuo
    HEPATOLOGY, 2022, 76 : S1327 - S1328
  • [50] Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis
    Peng, Tzu-Rong
    Weng, Yi-Fang
    Wu, Ta-Wei
    Wu, Chao-Chuan
    Chou, Yi-Chun
    Hsu, Ching-Sheng
    CANCERS, 2024, 16 (16)
12345